Table 1 Clinical demographics of overall population.
From: Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
Characteristics | Nº (216) |
|---|---|
Age | |
Median | 64 |
Range | 32–93 |
Sex | |
Male, n(%) | 110 (51%) |
Female | 106 (49%) |
Staging AJCC 8ºedition | |
I | 32 (15%) |
II | 49 (22%) |
III | 36 (17%) |
IV | 99 (46%) |
Deceased | |
Yes | 138 (64%) |
No | 78 (36%) |
Stages I and II | No. (81) |
Resectable pancreatic cancer | 54 (67%) |
Borderline pancreatic cancer | 27 (33%) |
Adjuvant chemotherapy in upfront resected | No. (41) |
mFOLFIRINOX | 28 (68%) |
Gemcitabine-based | 13 (32%) |
Neoadjuvant intent chemotherapy regimens | No. (34) |
mFOLFIRINOX | 32 (94%) |
Gemcitabine-based | 2 (6%) |
